CD8A and infection: Most studies and clinical trials on cytoimmunotherapy were performed with CD8+ T cells specific for the hCMV tegument protein UL83/pp65, because it was known to induce high frequencies of cytolytic CD8+ T lymphocytes (CTL) in natural infections [46,47,48,49], although the unusual expansion of these cells [49] may actually have indicated a low protective efficacy in preventing hCMV reactivation from latency.